Company news
Enzolytics Inc. news in 2022
Enzolytics Inc.'s news releases, calls and decks from 2022, newest first.
Enzolytics, Inc. Announces the Completion of the 2020 and 2021 Audited Financials
December 18, 2022
Enzolytics, Inc. Announces U.S. Distribution of IPF Immune(TM) and Progress in each of its Therapeutic Platforms
December 12, 2022
Enzolytics Recognizes World AIDS Day and Highlights the Company's Focus on Producing Effective Therapies for Treating HIV
November 30, 2022
Enzolytics, Inc. Announces Expansion of Production of Its Monoclonal Antibody Therapeutics and Marketing of IPF Immune(TM)
November 15, 2022
Enzolytics, Inc. Announces New Advisory Board Member
October 23, 2022
Enzolytics Reports Successful Completion of an MTD Tolerability Study of Its ITV-1 anti-HIV Therapeutic Leading to the Start of a 28-day GLP Toxicology Study
October 4, 2022
Enzolytics Inc. Announces Collaboration with Abveris to Discover Monoclonal Antibodies
September 15, 2022
Enzolytics Inc. Announces Litigation Success, Accounting Progress and Removal of "Yield" Sign on OTC Markets Stock Quotes
September 13, 2022
Enzolytics Announces the International Patent Office Search Report finding Novelty and Inventiveness in the Company's Pending International Patent Application Covering its anti-HIV Monoclonal Antibodies.
July 27, 2022
Enzolytics Announces the Discovery of Conserved Target Sites on the Monkeypox Virus
June 20, 2022
CORRECTION: Enzolytics, Inc. Reports Progress and Future Plans
April 24, 2022
Enzolytics, Inc. Reports Progress and Future Plans
April 24, 2022
Enzolytics Highlights Its Comprehensive PCT Patent Applications Covering Discovered Conserved Target Epitopes on the SARS-CoV-2 and HIV Viruses
March 24, 2022
Enzolytics, Inc. Highlights the Introduction of IPF Immune(TM) as CRN Data Shows Record-Breaking Number of Americans Use Dietary Supplements
March 22, 2022
Enzolytics, Inc.'s Wholly Owned Subsidiary Virogentics, Inc. Reports Progress on the Delivery of its ITV-1 Anti-HIV Therapeutic for Use by Patients in African Regions
March 13, 2022
Enzolytics IPF Immune(TM), an Immune Modulator, Is Introduced into the U.S. Market This Month
March 9, 2022
Enzolytics Announces Its New Technology For Entry Into The In-Vitro Diagnostics Market
February 20, 2022
Enzolytics, Inc. Announces Production and Sale in North America of “Enzolytics IPF Immune(TM)”, A New Dietary Supplement That Enhances the Immune System
January 3, 2022